Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
75 participants
INTERVENTIONAL
2020-07-01
2021-01-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Evaluation of a Silicone Hydrogel Daily Wear Monthly Replacement Contact Lens
NCT04422990
A Prospective, Randomized, Double-blind, Parallel, Active-controlled Clinical Study of Silicone Hydrogel Monthly Soft Contact Lens for the Safety and Effectiveness in Visual Correction.
NCT06121531
Clinical Evaluation of a Daily Wear Silicone Hydrogel Lens
NCT04207749
A Study to Evaluate the Clinical Performance and Safety of UNICON Silicone Hydrogel Daily Disposable Soft Contact Lenses
NCT07322211
Clinical Assessment of a Daily Wear Monthly Replacement Silicone Hydrogel Toric Contact Lens
NCT05211739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test Device: Qualis Silicone Hydrogel Soft Contact Lens
Test lenses will be worn on a daily wear basis for up to one month with removal for cleaning, disinfection, and storage prior to sleeping. Subjects will be instructed to wear the test lenses at least 6 hours a day, a minimum of 5 days per week. The Test Device is investigational and not cleared/approved by the US FDA.
soft (hydrophilic) contact lens
The intervention is a daily wear soft contact lens
Control Device: Acuvue Vita Monthly Contact Lens
Test lenses will be worn on a daily wear basis for up to one month with removal for cleaning, disinfection, and storage prior to sleeping. Subjects will be instructed to wear the test lenses at least 6 hours a day, a minimum of 5 days per week. The Control Device is cleared by the US FDA.
soft (hydrophilic) contact lens
The intervention is a daily wear soft contact lens
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
soft (hydrophilic) contact lens
The intervention is a daily wear soft contact lens
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
* The subject must be at least 18 years of age.
* The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 in each eye.
* The subject's refractive cylinder must be ≤ 0.75 Diopters in each eye.
* The subject must have best corrected visual acuity of 20/25 (LogMAR) or better in each eye.
* Subjects should own a wearable pair of spectacles.
* The subject must have normal eyes (i.e., no ocular medications or infections of any type).
* Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week
Exclusion Criteria
* Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
* Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
* The use of systemic or ocular medications that would contraindicate contact lens wear.
* Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion by keratometry.
* Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), etc.).
* Any grade 2 or greater slit lamp findings for corneal staining, and any grade 3 or greater slit lamp findings for other abnormalities (e.g., edema, corneal neovascularization, tarsal abnormalities, conjunctival injection) on the ISO 11980 classification scale, any current inflammatory events or events within the last 6 months, or any other ocular abnormality that may contraindicate contact lens wear.
* Any known hypersensitivity or allergic reaction to Biotrue or ClearCare contact lens care solutions
* Any ocular infection, allergy or clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca, ocular hypertension), or ocular conditions (e.g. strabismus), which might interfere with the study.
* Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
* Extended wear, monovision or multi-focal contact lens correction.
* Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
* Any subject where the randomized lens demonstrates a fit that is deemed inappropriate by the investigator, including, but not limited to, the lens being too flat, too steep, have excessive or inadequate movement, and/or insufficient limbal coverage.
* Employee or relative of employees of sponsor or investigational clinic (e.g., Investigator, Coordinator, Technician)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Unicon Optical Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ala Moana Advanced Eye Clinic
Honolulu, Hawaii, United States
SUNY College of Optometry
New York, New York, United States
The Ohio State University
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US-PRO1904001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.